Non-invasive Assessment for Outcome Prediction in Patients With Hepatocellular Carcinoma

Recruiting Observational Study
HCC - Hepatocellular Carcinoma Cirrhosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
159 (estimated)
Sponsor
Chinese University of Hong Kong · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a single-centre, prospective cohort study. Consecutive patients with compensated liver disease and hepatocellular carcinoma (HCC) for curative-intent treatment will be invited to this study. The study follow-up duration will be five years. The primary outcome is the composite of incident high-risk varices, hepatic decompensation and liver-related mortality. The participants will undergo tr…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Aged 18 or above * Known chronic liver disease(s) * HCC for curative-intent treatment (defined by HCC diagnosed with typical radiological features or histology, and planned for surgical resection or local ablative therapy as a curative-intent treatment) Exclusion Criteria: *…
Contacts

Jimmy CT Lai, MB ChB

85235054205

jimmyctlai@cuhk.edu.hk

CONTACT

Angel Chim, MSc

angelchim@cuhk.edu.hk

CONTACT